Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwMyeloma 2015 | Immunotherapy for the treatment of multiple myeloma

David Avigan • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma Antibodies Checkpoint inhibitors

At the Myeloma 2015, Dr David Avigan (Beth Israel Deaconess Medical Center, Boston, MA) discusses the development of immune checkpoint inhibitors, including anti-PD-1 antibodies, for the treatment of multiple myeloma (MM). An emerging focus has been on combination therapies and enhancing the anti-MM immune response during treatment using vaccination approaches.

More from David Avigan

2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
1:10
Immune dysregulation in myeloma and impact on disease progression
David Avigan • 26 Aug 2022
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals